Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but were mixed on operational cash flow: Net loss was $3.93M (EPS -$0.04) vs. the expected $5.62M loss (EPS -$0.06), primarily driven by a 55% YoY reduction in R&D expenses as Phase 2 trial activities wound down. Grant income of $3.5M met funding needs but declined 50% YoY, tracking lower clinical trial activity. Cash from operations was -$8.6M for the first half, trending slightly worse than the -$6.9M projected for the single quarter, though cash runway is secured into Q4 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cognition Therapeutics(CGTX) the EBIT is -7.738 M (+44.64%), Beat estimate;the EPS is -0.04 (+63.64%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B44.64%
-0.01B22.74%
+0.00B21.90%
EPSExceed expectations
-0.0463.64%
-0.063342.43%
+0.023321.21%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf